Arcellx (ACLX) Shares Outstanding (Diluted Average) (2021 - 2025)
Arcellx's quarterly Shares Outstanding (Diluted Average) came in at $56.3 million in Q4 2025, up 5.11% year-on-year from $53.6 million in Q4 2024, and little changed quarter-over-quarter from $56.6 million in Q3 2025.
Arcellx has reported Shares Outstanding (Diluted Average) for 5 years, with the latest figure at $56.3 million in Q4 2025.
- For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 5.11% year-over-year to $56.3 million; the trailing twelve-month figure through Dec 2025 stood at $56.3 million (up 5.11% YoY), and the FY2025 full-year result was $56.3 million, up 5.11% from the prior year.
- Shares Outstanding (Diluted Average) for Q4 2025 stood at $56.3 million, roughly flat from $56.6 million in the prior quarter.
- The five-year high for Shares Outstanding (Diluted Average) was $56.6 million in Q3 2025, with the low at $337302.0 in Q1 2021.
- Average Shares Outstanding (Diluted Average) over 5 years is $37.4 million, with a median of $47.6 million recorded in 2023.
- Year-over-year, Shares Outstanding (Diluted Average) jumped 8044.59% in 2022 and increased 4.74% in 2025.
- Tracing ACLX's Shares Outstanding (Diluted Average) over 5 years: stood at $446379.0 in 2021, then jumped by 8044.59% to $36.4 million in 2022, then jumped by 32.2% to $48.1 million in 2023, then rose by 11.45% to $53.6 million in 2024, then advanced by 5.11% to $56.3 million in 2025.
- The last three Shares Outstanding (Diluted Average) figures came in at $56.3 million (Q4 2025), $56.6 million (Q3 2025), and $56.2 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 3.06 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 810.00 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 118.76 Bn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 256.30 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 107.70 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 138.23 Mn |
| 10 | Arcellx | 6.48 Bn | 6.48 Bn | - | 56.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 56.31 Mn |
| Sep 30, 2025 | 56.59 Mn |
| Jun 30, 2025 | 56.22 Mn |
| Mar 31, 2025 | 55.26 Mn |
| Dec 31, 2024 | 53.57 Mn |
| Sep 30, 2024 | 53.37 Mn |
| Jun 30, 2024 | 53.52 Mn |
| Mar 31, 2024 | 52.76 Mn |
| Dec 31, 2023 | 48.06 Mn |
| Sep 30, 2023 | 47.78 Mn |
| Jun 30, 2023 | 47.44 Mn |
| Mar 31, 2023 | 46.77 Mn |
| Dec 31, 2022 | 36.36 Mn |
| Sep 30, 2022 | 33.81 Mn |
| Jun 30, 2022 | 28.73 Mn |
| Mar 31, 2022 | 20.76 Mn |
| Dec 31, 2021 | 446,379.00 |
| Sep 30, 2021 | 422,825.00 |
| Jun 30, 2021 | 437,258.00 |
| Mar 31, 2021 | 337,302.00 |